In a recent study published in the journal Nature Human Behaviour , researchers used a large, binational cohort (total n = 4,731,778) to investigate the short- and long-term associations between SARS-CoV-2 infections and subsequent adverse neuropsychiatric outcomes. They used exposure-driven propensity score matching to compare their samples’ outcomes against the general population and individuals with a non-SARS-CoV-2 respiratory infection. Study: Short- and long-term neuropsychiatric outcomes in long COVID in South Korea and Japan .
Image Credit: Kateryna Kon / Shutterstock Study findings revealed that COVID-19 survivors were at significantly heightened risk of developing cognitive deficits, insomnia, encephalitis, and at least four other neuropsychiatric sequelae. Specific conditions included Guillain-Barré syndrome (aHR, 4.63), cognitive deficit (aHR, 2.
67), insomnia (aHR, 2.40), anxiety disorder (aHR, 2.23), encephalitis (aHR, 2.
15), ischaemic stroke (aHR, 2.00), mood disorder (aHR, 1.93), and nerve/nerve root/plexus disorder (aHR, 1.
47). Encouragingly, vaccination was observed to attenuate the neuropsychiatric effects of the infection. These results are particularly interesting to clinicians and healthcare policymakers as they imply that the early management of COVID-19 may help their patients’ short- and long-term mental health.
The severe acute respiratory syndrome coronavirus 2 (SARS‐CoV‐2) caused coronavirus disease 2019 (COVID-19) pandemic remains one of .
